Bromodomain Inhibition in Diffuse Large B-cell Lymphoma-Giving MYC a Brake

被引：17

作者：

Mottok, Anja ^{[1
,2
]}

Gascoyne, Randy D. ^{[1
,2
]}

机构：

[1] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 1L3, Canada

[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 01期

关键词：

RITUXIMAB PLUS CYCLOPHOSPHAMIDE; BET BROMODOMAINS; VINCRISTINE; DOXORUBICIN; PREDNISONE; EXPRESSION; CANCER;

D O I：

10.1158/1078-0432.CCR-14-1651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bromodomains are conserved protein regions that function as epigenetic readers by recognizing specific histone modifications. The common association of bromodomains with enhancer and super-enhancer regions in diffuse large B-cell lymphoma contributes to its pathogenesis. Bromodomain inhibition reduces tumor growth largely through the disruption of transcriptional networks driven by oncogenic MYC. (C) 2014 AACR.

引用

页码：4 / 6

页数：3